Project Grant R01AI201543
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $795K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Cincinnati Children's Hospital Medical Center $243,000 on May 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to model fibroblast-cholangiocyte interactions in chronic ductopenic rejection using primary human cholangiocyte organoids. Chronic ductopenic rejection is the most common immunologic cause of liver allograft loss in children. The research uses human liver tissue samples and...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $822,280 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on intragraft alloreactive T cells in human solid organ transplantation, with the goal of controlling rejection after transplantation. The research dissects intragraft T cell alloimmunity using longitudinal surveillance biopsies from intestinal...
- The National Institute of Allergy and Infectious Diseases awarded $836,711 to The Trustees of Columbia University in the City of New York on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate whether selective matching of donor and recipient major histocompatibility complex class II molecules decreases rejection and promotes regulatory tolerance in intestinal transplantation. The research addresses high rejection rates in intestinal...
- The National Institute of Allergy and Infectious Diseases awarded Sloan-Kettering Institute for Cancer Research $3,519,992 on March 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop computational and microbiome-based strategies for predicting and preventing gut-borne bloodstream infections in immunocompromised patients. The project will develop three integrated tools: computational models to forecast infection risk based on microbiome dynamics,...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, Baltimore $770,199 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how metabolic rewiring driven by gut microbiome changes influences immune outcomes in chronic cardiac transplant rejection. The research employs a murine model of chronic cardiac rejection with full MHC mismatch and clinically relevant chronic immunosuppression to study how...
- The National Institute of Allergy and Infectious Diseases awarded Boston Children's Hospital $847,299 on August 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immunomodulatory mechanisms in allograft rejection. The project, titled "Regulation of Alloimmunity by Intragraft Endothelial Cells," examines how graft microvascular endothelial cells suppress alloimmune responses during transplant rejection. The research will characterize...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $254,529 on May 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop B-TOL, a multifunctional recombinant fusion protein designed to regulate transplant rejection through simultaneous blockade of the CD154/CD40 costimulatory pathway and promotion of regulatory T cell differentiation. The research addresses limitations in current transplant immunosuppression...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $750,787 on July 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate central memory stem-cell-like follicular helper T cells (CTFH) and their contribution to durable donor-specific anti-HLA antibodies (DSA) and chronic antibody-mediated rejection (ABMR) in kidney transplant recipients. The research addresses mechanisms of chronic rejection in solid organ...
- The National Institute of Allergy and Infectious Diseases awarded $436,454 to Massachusetts General Hospital on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate gastrointestinal tract-driven T cell reprogramming during acute graft-versus-host disease (AGVHD). The recipient will conduct research across three specific aims examining how the gastrointestinal tract drives systemic alloimmunity in patients after allogeneic hematopoietic cell...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, Baltimore $777,421 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize immunomodulation strategies for cardiac xenograft transplantation. The recipient is conducting research to overcome rejection mechanisms in cardiac xenotransplants, building on prior work within the IXCRP Consortium that led to the world's first two human cardiac...